Skip to main content

INVESTOR ALERT: Investigation of Unilife Corporation Announced by Law Offices of Howard G. Smith

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Unilife Corporation (“Unilife” or the “Company”) (NASDAQ: UNIS) concerning the Company and its officers’ possible violations of federal securities laws.

Unilife designs, manufactures, and supplies injectable drug delivery systems in the United States and internationally. The Company announced on May 9, 2016, that it was postponing its earnings call due to discovery of violations of company policy and possible violations of laws by the former Unilife CEO; and, that the Company is investigating these issues and potential effect on financial reporting and internal controls. On this news the Company’s shares fell sharply in value.

On May 23, 2016, Unilife announced that it has received a deficiency letter from NASDAQ for failing to file its financial reports within the required period. On this news, shares of Unilife have fallen over 11% to just $2.61 per share during intra-day trading on May 24, 2016.

If you purchased Unilife securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.